Kantar Health Adds Five New Tumor Types to CancerMPact(R) Treatment Architecture China
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/12/11 -- , a leading healthcare-focused global consultancy and marketing insights company with special expertise in oncology, announces the addition of five new tumor types to CancerMPact® Treatment Architecture China. A subscription to CancerMPact® Treatment Architecture China provides in-depth analysis of the current clinical management of cancer in China by stage of disease for all treatment modalities, including chemotherapy, through multiple lines of therapy in key tumor types.
"Large, multinational pharmaceutical companies are investing more and more in emerging markets, especially China," Senior Vice President Bill Bagwell says. "However, China is extremely different from Western markets, from the most prevalent tumor types to how patients are diagnosed and ultimately treated. It is imperative for companies to understand how drug affordability affects the use of Western standards of care in China's growing oncology market. Treatment Architecture China offers this information and is constantly being updated to address our clients' business needs."
The latest enhancement to CancerMPact® Treatment Architecture China includes the addition of the following tumor types:
Brain
Chronic Myeloid Leukemia
Melanoma
Multiple Myeloma
Renal Cell Carcinoma
Information and analyses are also available for:
Acute Myeloid Leukemia
Breast
Colorectal
Gastric
Head and Neck
Hepatocellular
Non-Hodgkin's Lymphoma
Non-Small Cell Lung
Ovarian
Pancreatic
Prostate
CancerMPact® Treatment Architecture China supports actionable decision-making in the Chinese pharmaceutical market, providing pharmaceutical companies with the clinical depth and insight to:
Develop strategies to capitalize on opportunities, such as where to introduce new therapeutic regimens
Compare treatment modalities across China, Japan, Europe and the U.S.
Produce more accurate market assessments and product forecasts, leading to achievable sales goals
Gain perspective on targeted audiences regarding whom they treat and how they treat them
Plan product positioning to take advantage of a dynamic market on the verge of introducing universal healthcare coverage
Kantar Health is a global, evidence-based decision support partner to the world's leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.
With offices in over 30 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.
For more information on Kantar Health, please contact
Paula Paradise
Vice President of Global Marketing
+1-484-442-1431
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.10.2011 - 08:06 Uhr
Sprache: Deutsch
News-ID 1045125
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Health & Nutrition
Anmerkungen:
Diese Pressemitteilung wurde bisher 144 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Kantar Health Adds Five New Tumor Types to CancerMPact(R) Treatment Architecture China
"
steht unter der journalistisch-redaktionellen Verantwortung von
Kantar Health (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
